Compare NRT & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | PLUR |
|---|---|---|
| Founded | 1975 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 34.9M |
| IPO Year | N/A | N/A |
| Metric | NRT | PLUR |
|---|---|---|
| Price | $6.25 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 63.6K | 47.2K |
| Earning Date | 12-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 12.90% | N/A |
| EPS Growth | ★ 24.05 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $6,184,173.00 | $1,326,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $10.59 | ★ N/A |
| Revenue Growth | 18.55 | ★ 121.74 |
| 52 Week Low | $3.88 | $3.02 |
| 52 Week High | $6.95 | $7.13 |
| Indicator | NRT | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 38.75 |
| Support Level | $6.10 | $3.10 |
| Resistance Level | $6.61 | $3.92 |
| Average True Range (ATR) | 0.26 | 0.31 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 66.25 | 7.03 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.